InsiderClue
← All stocks

Dianthus Therapeutics, Inc. /DE/

DNTH Scheduled selling only
CIK 0001690585 #1220 in the set updated 17 Sep 2026
Bought (12 mo)
$0.00
out of their own pocket, the only kind of buying there is
Sold (12 mo)
$69.18M
$0.00 on a plan · $69.18M straight out of an exercise
Sold at will
$0.00
0 of 61 sales
Net
−$69.18M
$0.00 against sales at will

By person

9 insiders · 64 transactions
11.0×

Marino Garcia holds 11.0 times base salary in stock. $6.97M of shares against $630.00K in salary for 2025.

Salary from the company's own proxy. The shares are what Marino Garcia last reported holding, valued at $106.74, the price Common Stock was last bought or sold at on the open market here, on 1 Sep 2026.

Insider
Role
Bought
Sold
Net
Holding
Of company
Worth
Change
Garcia Marino
CEO AND PRESIDENT
—
$27.96M (12) scheduled
−$27.96M
65,292
0.1167%
$6.97M
—
Randhawa Simrat
EVP, Head of R&D
—
$15.00M (11) scheduled
−$15.00M
4,000
0.0072%
$426.96K
0.0%
Savitz Ryan
EVP, CFO & CBO
—
$14.29M (13) scheduled
−$14.29M
0
0.0000%
$0.00
—
Veness Adam M
SVP, General Counsel and Sec.
—
$4.63M (5) scheduled
−$4.63M
15,000
0.0268%
$1.60M
—
CARR EDWARD
CHIEF ACCOUNTING OFFICER
—
$3.56M (5) scheduled
−$3.56M
0
0.0000%
$0.00
—
Soteropoulos Paula
Director
—
$2.25M (3) scheduled
−$2.25M
0
0.0000%
$0.00
—
McGeorge Anne
Director
—
$844.82K (5) scheduled
−$844.82K
0
0.0000%
$0.00
—
Read Simon
Director
—
$630.79K (7) scheduled
−$630.79K
0
0.0000%
$0.00
—
Fairmount Funds Management LLC entity
Director
—
—
—
0
0.0000%
$0.00
−100.0%

Individual transactions

3
Insider
Date
Role
Action
Shares
Price
Amount
Veness Adam M
13 Aug 2026
SVP, General Counsel and Sec.
Exercised, kept
15,000
$18.17
$272.55K
Garcia Marino
16 Mar 2026
CEO AND PRESIDENT
Exercised, kept
5,592
$17.88
$99.98K
Garcia Marino
16 Mar 2026
CEO AND PRESIDENT
Exercised, kept
59,700
$6.70
$399.99K
Show all 64 transactions →

What was left out

Form 4 filings counted 36
Amendments (4/A) skipped 0
Filings about a different issuer 0
Unreadable filings 0
Joint filings 0
Sales on a Rule 10b5-1 plan 0
Sales straight out of an exercise 61
Sales at will 0
Transactions with no price 0
Shares from compensation/vesting 958,851
History held since 27 Jun 2018